PATENT CLAIM ANALYSIS

Application Number: 15957122
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "009600"]

Abstract:
The invention relates to treatment and prevention of heart failure in a mammal. The invention provides a dosing regimen whereby the therapeutic benefits conferred by administration of peptide comprising an epidermal growth factor-like domain, e.g., a neuregulin such as glial growth factor 2 (GGF2) or a functional fragment thereof, are maintained and/or enhanced, while concomitantly minimizing any potential side effects.

Claim (Index 18):
The method of  claim 9 , further comprising administering a therapeutically effective amount of a benzodiazepine.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 91.0
- Lexical Diversity: 1.19298
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['13904654', '14928124', '13059206', '15357586', '14844475']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7503760178401389
- 35 USC 102 Novelty (BERT): 0.5557357841608358
- Combined Prediction Score: 0.7309119944722086
- Mean Citation Score: 367.206068
- Max Citation Score: 440.68204
- Similarity Product: 280.7256598095012

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test